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Purpose/Objective: Rotational IMRT (rIMRT, tradenames VMAT(R), 
RapidArc(R)) has set new standards for the speed of treatment 
delivery. However, today's treatment machines are not optimized for 
this kind of delivery, with the consequence that design constraints on 
leaf and gantry rotation speeds and dose rates limit the achievable 
treatment times. Here, we explore the questions of how a specialized 
linac for rIMRT would have to be designed, and which treatment times 
are ideally achievable without loss of plan quality, relative to the best 
dose distributions achievable today. 
Materials and Methods: The fundamental design of the hypothetical 
linac comprises: a continuously rotating gantry with a cone beam and 
a conventional MLC, a continuously variable dose rate with 
instantaneous beam switching, and a fixed patient position. Variable 
parameters were leaf and gantry rotation speed as well as maximum 
and minimum dose rate. The linac was modelled in a research version 
of a commercial TPS, being capable of rIMRT planning including 
segment shape optimization (direct aperture optimization). The leaf 
sequencing algorithm was specifically developed for this virtual linac, 
and determines the optimum leaf trajectories from the minimization 
of a complex cost function which comprises the input from multiple 
gantry angles simultaneously. It also finds the required number of full 
rotations. Planning studies were performed on cases of variable 
complexity to determine the combination of leaf and gantry speed 
which allows for the shortest delivery times. 
Results: There appear to be two fundamentally different paths 
towards fast delivery times: for a slow moving gantry, fast leaves are 
obviously an advantage to increase the modulation per sector of the 
gantry rotation, because treatments with few full rotations are 
favoured. The other mode is an extremely fast rotating gantry (10-20 
RPM), combined with a larger number of rotations and relatively low 
modulation per sector of the gantry rotation. Modulation is then 
achieved by multiple passes of the beam over the same sector. Both 
methods are capable of delivering the high quality of treatment plan 
possible with a modern state-of-the-art linac (reference plans were 2-
arc plans for Varian TrueBeam(R) and Elekta Agility(R) linacs). Lower 
treatment times were achievable with the fast gantry rotation. The 
minimum was obtained at around 20 RPM/18 seconds for prostate 
cases, and 12 RPM/45 seconds for complex head-and-neck cases with 
3 dose levels. Optimum max dose rates were 1200-1800 MU/min. Even 
faster gantry speed resulted in a greater number of beam interrupts 
and larger sectors of gantry rotation 'in the dark' and therefore more 
full rotations for realistic leaf speeds. 
Conclusions: A planning study for a hypothetical, yet realistic, 
continuously rotating linac design with a novel type of leaf sequencing 
algorithm shows, that today's quality of dose distribution can be 
achieved with delivery times in the order of 20-45 seconds.  
   
 SYMPOSIUM: DOSE-DENSITY IN LUNG CANCER  
  
SP-0288   
Dose-fractionation in SBRT, the evolution towards central lesions  
U. Nestle1 
1Universitätsklinik Freiburg, Radiation Oncology Department, 
Freiburg, Germany  
 
The advent of SBRT for lung tumors has opened new horizons in the 
curative radiotherapyf or lung cancer. In peripheral lesions, very high 
local control rates have throughout been reported after high dose 
hypofractionated radiotherapy. Besides high precision and small 
volumes, extreme treatment acceleration is a key feature for this 
success. 
Therefore it is tempting to translate the successful concept of SBRT to 
more central lesions. However, while peripheral lesions are mainly 
surrounded by lung, the normal tissue neighborhood of central lesions 
is challenging and reports of severe and fatal normal tissue toxicities 
like bleedings and necroses have caused concerns.  
On the other sides some patient cohorts with encouraging results after 
SBRT of central lesions have been observed after the use of less 
hypofractionated SBRT strategies raising the question of “overkill” by 
other dose/fractionation regimes. 
In order to approach this issue scientifically, clinical studies are 
needed to prospectively assess not only local control but also toxicity. 
Current study concepts will be discussed. 
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Experimental and clinical evidence for time-dose-fractionation in 
locally advanced non-small cell lung cancer as the basis for dose-
escalation will be reviewed and strategies to improve outcome after 
radiotherapy will be discussed. An essential component of these 
strategies represents advanced technology in planning and treatment 
delivery such as motion management, image-guidedance and 
functional imaging.  
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Optimising the management of patients with LDSCLC continues to be a 
challenge. The relevant role of radiotherapy was clearly demonstrated 
in the early 1990’s with two meta-analyses which established a 
survival benefit for patients treated with radio-chemotherapy, 
however, the optimal method of integrating thoracic radiotherapy 
(TRT) with chemotherapy remained undefined.  
To date, some topics are still controversial: the optimal timing of 
radiotherapy, the radiation dose, the fractionation and the combined 
chemotherapy regimen.  
The rationale for an early administration of radiation therapy during 
the course of chemotherapy may be to eliminate localized populations 
of chemotherapy-resistant tumour cells that might be responsible for 
treatment failure if permitted to disseminate systemically. This would 
be an obvious advantage of early administration of radiotherapy. Of 
the seven randomized controlled trials examining timing, only those 
with early chemoradiation have 5-year survival rates in excess of 20%. 
The "chemoradiation package" can be defined as the time from the 
start of chemotherapy until the completion of radiotherapy. The best 
median survival and long-term survival rates have been observed in 
trials with a chemoradiation package time of less than 6 weeks. 
Several phase III trials investigated the timing and sequencing of 
radiotherapy. Fried et al. reported a meta-analysis carried out 
regarding the timing of radiotherapy. Six out of seven randomised 
trials, with a total of 1524 patients, favoured the use of early 
radiotherapy, and the overall risk ratio at 2 years was 1,17 (95%CI 
1,02- 1,35; p=0,03) favouring the use of early radiotherapy. The 
subgroup analysis revealed that the benefit of the early radiotherapy 
schedule was seen in patients receiving hyperfractionated radiation 
and/or platinum based compared  chemotherapy (18% of absolute 
benefit).  
More recently, a significant relationship between the value of the 
time lapse from the first day of chemotherapy to the end of thoracic 
radiotherapy (SER), as well as overall survival and disease free 
survival, was reported. The analysis on 212 patients with limited stage 
SCLC shows that each day of extension of the SER resulted in 
increased probability of death (decrease of OS) by 0.28% and an 
increase of  the risk of development failure (decrease of DFS) by 
0.31%.   
Historically, total doses of 40-50 Gy delivered in 1,8-2,0 Gy daily 
fractionation have been utilized in once daily radiation schemes. 
Clinical results comparing standard fractionation (SF) with total doses 
less than 54Gy and more than 54Gy or accelerated fractionation (AHF) 
show that for the local control rates, the overall and progression-free 
survival rates, all outcomes were significantly lower in the SF <54 Gy 
group than in the other two groups, although no significant difference 
was found between the AHF and SF ≥54 Gy groups.  
With regard to fractionation, the customary once daily radiotherapy 
dose divided into two treatments each day has biologic advantages. In 
vitro, small-cell lung-cancer cell lines have marked radio-sensitivity 
even to small doses of radiation. The cornerstone trail is certainly 
Turrisi’s one, an intergroup phase III study, in which accelerated 
hyperfractionation was superior to standard fractionation. At the five 
year follow-up, the difference between the treatments favoured the 
twice-daily treatment group by 10 percent in comparison with 
standard fractionation. As expected, esophageal toxicity was 
increased (G3 27% vs 11%, respectively).  
More recently, a meta-analysis on modified fractionation on 685 
patients with a median follow-up of 12.1 years and 622 deaths was 
published. The effect of modified RT on overall survival was absolute 
benefit of 1.7% at 3 years (from 29.6% to 31.3%) and 5.1% at 5 years 
(from 18.7% to 23.8%).  
Only carefully conducted prospective clinical trials will allow us to 
further improve local control and survival rates of LD-SCLC patients in 
the future. 
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Dose escalation or intensification by radiation is built on the premise 
that  higher biological doses will lead to better local tumour control. 
Obviously, the ultimate goal should be to obtain uncomplicated cures.  
From a theoretical point of view, both the improvement of techniques 
or the ability to understand the biology of radiation damage to the 
normal tissues resulting in appropriate patient selection and 
pharmacological interventions will increase the therapeutic ratio. 
Radiotherapy techniques have improved dramatically over the last 
decade, now enabling to use IMRT and Volumetric Modulated Arc 
Radiotherapy in daily practice. This results in the possibility to deliver 
high dose radiation in patients that once were deemed to receive 
palliative doses. The on-going developments in on-line adaptation will 
further improve this evolution. Other new developments include dose 
re-distribution studies in which the whole PTV no longer receives an 
homogeneous dose, but a higher dose is delivered on the basis of 
molecular imaging characteristics. In many patients, this allows 
further dose escalation with equal doses to normal tissues. However, 
in the PET-boost study, the mediastinal structures were the most 
frequent dose-limiting (van Elmpt et al; Radiother Oncol 2012). Proton 
therapy has been shown to allow further dose escalation in many 
theoretical planning studies.       
However, knowledge about the biological characteristics of OARs of 
individual patients would allow stratification into risk groups for side 
effects and possibly pharmacological interventions as well. Many 
studies have been reported on the relation between SNPs and side 
effects of radiotherapy. Most results were retrospective and could not 
be replicated in independent prospective validation cohorts (Barnett 
GC et al. Lancet 2012). With better study design and standardisation 
as for instance advocated by the Radiogenomics Consortium, and 
newer techniques such as GWAS, robust genetic features for radiation 
toxicity may emerge (Talbot CJ et al. Br J Cancer 2012).  
In conclusion, dose escalation depends both on optimal techniques 
and biology, but much research remains to be done in order to build 
models and workflows with proven clinical value (Lambin et al. Nat 
Rev Clin Oncol. 2012). 
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Clinical guidelines are recommendations on how healthcare 
professionals should care for people with specific conditions. The 
recommendations are based on the best available evidence. Until 
recently, the highest level of evidence was considered to be derived 
from randomized clinical trials, or even better, meta-analyses of 
randomized clinical trials. Undoubtedly, clinical trials are essential 
but many factors limit their success, such as the costs of long-term 
follow-up, and participants often not being representative of the 
general population. In the last decade, realization that population 
based databases may help in evaluating the generalizability of clinical 
guidelines has emerged. However, one has to be aware of the pitfalls 
of population based databases. Even population-based databases can 
contain a selection bias, and the assumption that the patients in the 
database are a valid representation of the target group should always 
be tested. In addition, the accuracy of the data has to be monitored, 
as well as the setting in which the data have been collected. To make 
optimal use of population-based databases, comorbidity should be 
reported as well. For radiotherapy in particular, registration of the 
treatment details and information on long-term follow-up should be 
provided to ensure adequate evaluation of the treatment effects.  So 
far, most databases have been initiated by the surgical community or 
generated by for example National Health Services. The underlying 
motive has not so much been development of clinical guidelines, but 
more to implement a clinical auditing system that aims to provide a 
greater level of insight into the process and outcomes of patients who 
undergo medical treatment and to continuously improve this. In order 
to start this improvement cycle (the ‘audit cycle’), it is important to 
identify which quality aspects are important and where improvements 
are required. The most important objective of clinical auditing is to 
initiate a cycle for improvement on a national, regional and local 
level. The feedback that medical specialists are given regarding the 
care that they provide forms the catalyst for improvement initiatives. 
 Several European countries have implemented such audit for 
colorectal cancer, providing much inside in current standards of care. 
It has already resulted in demonstrable improvements in the 
treatment provided to colorectal patients. For example, 
improvements in adequate pre-operative imaging in colon cancer 
patients have been observed, as well as increases in the number of 
patients suffering from rectal carcinoma that were discussed in a 
multidisciplinary team prior to operation. This has resulted in an 
increase of administration of (neo-)adjuvant radiotherapy and an 
improved standard of pathological reporting regarding, for example, 
number of lymph nodes examined and the reporting of circumferential 
resection margins (CRM).  
In addition, results from the population based databases have 
identified the problems concerning frail elderly people. Half of 
patients suffering from bowel cancer are older than 70 years of age. 
Many of these elderly people have comorbidities and are vulnerable to 
both the increased occurrence of complications and the consequences 
thereof. These risks have been definitely confirmed in clinical audits 
and have resulted in awareness that although clinical guidelines 
should be suitable for most patients with a specific condition, 
identification of specific risk groups is warranted. 
In conclusion: clinical auditing is absolutely necessary to evaluate and 
refine clinical guidelines. However, there will always be a need for 
clinical trials to facilitate practice changing research. 
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“Radiomics” refers to the extraction and analysis of advanced 
quantitative imaging features in high throughput from medical 
images, including computed tomography (CT), positron emission 
tomography (PET) and magnetic resonance imaging (MRI) (Lambin et 
al. EJC 2012; ww.radiomics.org). Importantly, these features are 
designed to be extracted from standard-of-care images, leading to a 
very large potential subject pool.  Radiomic data are in a mineable 
form that can be used to build descriptive and predictive models. The 
core hypothesis of radiomics is that these models, which can include 
biological or medical ata, can provide valuable diagnostic, prognostic 
or predictive information.Also, relating image features to phenotypes 
or gene-protein signatures is being investigated. The radiomics 
enterprise can be divided into four processes, each with its own 
challenges that need to be overcome:  (1) image acquisition and 
reconstruction,(2) image segmentation and rendering, (3) feature 
extraction and qualification,(4) bioinformatic analyses. Each step, 
especially involving large datasets,poses unique challenges. The focus 
of this presentation will be on the predictive value of CT & FDG-PET 
radiomics features of non-small cell lung cancer and head and neck 
cancer, complemented by preclinical tumour data. Finally we will 
describe the current and potential applications of radiomics to other 
problems in oncology. 
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Over the past decade the progress in individualized medicine has 
posed major challenges also in radiotherapy of cancer diseases. The 
development of models for decision making seems crucial for taking 
advantage of inter- and intra-patient variability to maximize the 
therapeutic index in RT by increased tumour control and decreased 
normal tissue complications. Models depend to a high degree on 
validated predictors such as the tumour dose-response relationship, 
among many others. 
Using modern RT delivery techniques like IMRT and volumetric arc 
therapy in combination with in-room image-guidance complex dose 
distributions are administered to cover target and spare organs at risk 
with high spatial precision. However, the increasing use of volumetric 
imaging such as cone-beam CT during the fractionated treatment 
course allow for detection of changes in the patient anatomy and, 
thus, detect the temporal aspects in the delivered dose distribution 
which might deviate from the planned one. Utilization of delivered 
dose-response relationships is expected to increase the accuracy of 
prediction models. 
Several aspects are involved in the analysis of the CBCT image sets. 
The inferior image quality due to artefacts compared to conventional 
